Understanding the factors influencing chronic inflammatory skin diseases
Determinants of Chronic Inflammatory Skin Disease Trajectories
University Hospital Schleswig-Holstein · NCT05928169
This study is trying to understand what causes different types of chronic skin conditions, like eczema and psoriasis, to behave differently in patients over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 0 Years to 80 Years |
| Sex | All |
| Sponsor | University Hospital Schleswig-Holstein (other) |
| Drugs / interventions | dupilumab, tralokinumab |
| Locations | 1 site (Kiel) |
| Trial ID | NCT05928169 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the variability in clinical expression and progression of chronic inflammatory skin diseases such as atopic dermatitis, psoriasis, eczema, lichen, and alopecia areata. By conducting long-term clinical assessments and analyzing individual biomaterials, the study seeks to identify clinical and molecular factors that correlate with disease subtypes and progression. The research will involve a larger cohort of patients to confirm preliminary findings from pilot studies regarding disease heterogeneity and its underlying mechanisms.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with inflammatory skin diseases by a dermatologist who can provide informed consent.
Not a fit: Patients who are pregnant, breastfeeding, or currently participating in another clinical trial may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved patient management and personalized treatment strategies for chronic inflammatory skin diseases.
How similar studies have performed: Preliminary pilot studies have suggested potential success in identifying disease subtypes, but this study aims to confirm and expand upon those findings in a larger cohort.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * dermatologist-diagnosed inflammatory skin disease * informed consent Exclusion Criteria: * subject and/or the legal guardians are not able to give written informed consent * pregnant and breastfeeding women * concurrent participation in a clinical trial * use of systemic immunosuppressive therapy or phototherapy during the last 4 weeks or receipt of biologics therapy (e.g. dupilumab, tralokinumab) within the last 3 months * treatment of the target skin areas with topical corticosteroids, calcineurin inhibitors or emollients 24 hours before sample collection
Where this trial is running
Kiel
- Department of Dermatology and Allergy, University Hospital Schleswig-Holstein — Kiel, Germany (RECRUITING)
Study contacts
- Study coordinator: Stephan Weidinger, MD
- Email: sweidinger@dermatology.uni-kiel.de
- Phone: 0049431500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Atopic Dermatitis, Psoriasis, Lichen Planus, Alopecia Areata, Hidradenitis Suppurativa, Prurigo Nodularis, Cutaneous Lupus, Rosacea